Gordon Otto

661 total citations
30 papers, 405 citations indexed

About

Gordon Otto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Gordon Otto has authored 30 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 4 papers in Surgery. Recurrent topics in Gordon Otto's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (10 papers). Gordon Otto is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (10 papers). Gordon Otto collaborates with scholars based in United States, Germany and Japan. Gordon Otto's co-authors include Caroline E. Fife, Paul J. Sheffield, Robert A. Warriner, Jon T. Mader, Keith Brandt, Xiuning Le, Paul K. Paik, David Walker, Rolf Bruns and Enriqueta Felip and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Critical Care Medicine.

In The Last Decade

Gordon Otto

30 papers receiving 375 citations

Peers

Gordon Otto
Andrea Barbetta Italy
Rossella Montemurro Italy
Said Abisi United Kingdom
U Baccaglini Italy
Anders Ljung Sweden
T. Yamaoka Japan
Guillermo Ramos-Gallardo Mexico
A. Rogdakis Greece
Filipe Veloso Gomes Portugal
Himanshu Rai Germany
Andrea Barbetta Italy
Gordon Otto
Citations per year, relative to Gordon Otto Gordon Otto (= 1×) peers Andrea Barbetta

Countries citing papers authored by Gordon Otto

Since Specialization
Citations

This map shows the geographic impact of Gordon Otto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Otto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Otto more than expected).

Fields of papers citing papers by Gordon Otto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Otto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Otto. The network helps show where Gordon Otto may publish in the future.

Co-authorship network of co-authors of Gordon Otto

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Otto. A scholar is included among the top collaborators of Gordon Otto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Otto. Gordon Otto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Griesinger, Frank, Egbert F. Smit, Rémi Veillon, et al.. (2022). 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy. Annals of Oncology. 33. S40–S41. 2 indexed citations
2.
Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2022). O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION). Annals of Oncology. 33. S475–S475. 1 indexed citations
3.
Yang, James Chih‐Hsin, M-J. Ahn, Hiroya Sakai, et al.. (2022). 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping. Annals of Oncology. 33. S41–S42. 1 indexed citations
4.
Veillon, Rémi, Hiroshi Sakai, Xiuning Le, et al.. (2022). Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clinical Lung Cancer. 23(4). 320–332. 6 indexed citations
5.
Kato, Terufumi, James Chih‐Hsin Yang, Myung‐Ju Ahn, et al.. (2022). Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.. Journal of Clinical Oncology. 40(16_suppl). 9120–9120. 1 indexed citations
6.
Le, Xiuning, Luis Paz‐Ares, Jan P. van Meerbeeck, et al.. (2022). Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).. Journal of Clinical Oncology. 40(16_suppl). 9121–9121. 9 indexed citations
7.
Cui, Wanyuan, Nick Brown, Victoria Brown, et al.. (2022). Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience. Lung Cancer. 165. S38–S39. 2 indexed citations
8.
Morise, Masahiro, Hiroshi Sakai, Rémi Veillon, et al.. (2021). O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial. Annals of Oncology. 32. S291–S291. 2 indexed citations
9.
Garassino, Marina Chiara, Enriqueta Felip, Hiroshi Sakai, et al.. (2021). 1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC. Annals of Oncology. 32. S984–S985. 4 indexed citations
10.
Felip, Enriqueta, Marina Chiara Garassino, H. Sakai, et al.. (2021). P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy. Journal of Thoracic Oncology. 16(10). S1085–S1085. 5 indexed citations
11.
Viteri, Santiago, Julien Mazières, Rémi Veillon, et al.. (2021). MO01.46 Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC. Journal of Thoracic Oncology. 16(1). S35–S36. 1 indexed citations
12.
Viteri, Santiago, Julien Mazières, Rémi Veillon, et al.. (2020). 1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC. Annals of Oncology. 31. S831–S831. 6 indexed citations
13.
Stephens, Philip J., Travis Clark, Mark Kennedy, et al.. (2016). Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. Annals of Oncology. 27. vi401–vi401. 2 indexed citations
14.
Otto, Gordon & Andrea Lohse. (2011). Defizite bei der Erfassung transplantationsrelevanter Daten in Deutschland. Zeitschrift für Gastroenterologie. 49(12). 1549–1552. 1 indexed citations
15.
Fife, Caroline E., et al.. (2008). The safety of negative pressure wound therapy using vacuum‐assisted closure in diabetic foot ulcers treated in the outpatient setting. International Wound Journal. 5(s2). 17–22. 13 indexed citations
16.
Fife, Caroline E., et al.. (2007). Factors influencing the outcome of lower‐extremity diabetic ulcers treated with hyperbaric oxygen therapy. Wound Repair and Regeneration. 15(3). 322–331. 63 indexed citations
17.
Fife, Caroline E., et al.. (2007). Wound center facility billing: A retrospective analysis of time, wound size, and acuity scoring for determining facility level of service.. PubMed. 53(1). 34–44. 7 indexed citations
18.
19.
Fife, Caroline E., et al.. (2001). Incidence of pressure ulcers in a neurologic intensive care unit. Critical Care Medicine. 29(2). 283–290. 114 indexed citations
20.
Arnold, Jayantha, Thomas Kraus, Gordon Otto, et al.. (1992). Liver transplantation for acute or chronic liver failure by hepatitis non-A, non-B and hepatitis C viral infections: a postoperative follow-up.. PubMed. 30(8). 525–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Barbetta Breakdown of academic impact, for papers by Rossella Montemurro Breakdown of academic impact, for papers by Said Abisi Breakdown of academic impact, for papers by U Baccaglini Breakdown of academic impact, for papers by Anders Ljung Breakdown of academic impact, for papers by T. Yamaoka Breakdown of academic impact, for papers by Guillermo Ramos-Gallardo Breakdown of academic impact, for papers by A. Rogdakis Breakdown of academic impact, for papers by Filipe Veloso Gomes Breakdown of academic impact, for papers by Himanshu Rai
Rankless by CCL
2026